Company Analysis
Sign in

Codexis, Inc. (CDXS)

Nasdaq: CDXS · Industrial Organic Chemicals · Redwood City, CA · filing with the SEC since 2002
Full chart Alerts Compare
Grade4.4
◀ Past 4.4● Present 3.0▶ Future 6.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

463 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Codexis, Inc.’s names, not what it holds today.

Patents granted
463
463 utility, 1976 to Dec 31, 2025
Granted in 2025
42
Against 25 in 2024 and 21 in 2023
Applications published
590
31 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Biotechnology130
Pharmaceuticals18
Computer technology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Codexis, Inc. its own name
US, as the owner printed on each patent
463 granted
162 published
Codexis, Inc. its own name
named as the applicant on its applications, in US. 1 more under the same name are not counted (printed in RE)
0 granted
428 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 23, 202512,503,688Engineered transaminase polypeptidesBiotechnologyCodexis, Inc.
Nov 25, 202512,480,111Penicillin-G acylasesBiotechnologyCodexis, Inc.
Nov 25, 202512,480,104Engineered sucrose phosphorylase variant enzymesBiotechnologyCodexis, Inc.
Nov 25, 202512,480,100Ketoreductase polypeptides for the preparation of phenylephrineBiotechnologyCodexis, Inc.
Nov 25, 202512,480,099Engineered galactose oxidase variant enzymesBiotechnologyCodexis, Inc.
Nov 18, 202512,473,557Engineered guanylate kinase variant enzymesBiotechnologyCodexis, Inc.
Nov 4, 202512,460,195Engineered deoxyribose-phosphate aldolasesBiotechnologyCodexis, Inc.
Oct 21, 202512,448,611Transaminase polypeptidesBiotechnologyCodexis, Inc.
Sep 30, 202512,428,629Engineered uridine phosphorylase variant enzymesBiotechnologyCodexis, Inc.
Sep 23, 202512,421,532Polynucleotides encoding engineered imine reductasesBiotechnologyCodexis, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388940ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSBiotechnologyCodexis, Inc.
Dec 4, 20252025/0368967KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONESBiotechnologyCodexis, Inc.
Nov 13, 20252025/0346935KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (R)-3-HYDROXYTHIOLANEBiotechnologyCodexis, Inc.
Nov 13, 20252025/0346882PENICILLIN-G ACYLASESBiotechnologyCodexis, Inc.
Nov 13, 20252025/0346870ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSBiotechnologyCodexis, Inc.
Nov 6, 20252025/0340853ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSISBiotechnologyCodexis, Inc.
Oct 23, 20252025/0327042NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITYBiotechnologyCodexis, Inc.
Oct 16, 20252025/0320472ENGINEERED TRANSAMINASE POLYPEPTIDESBiotechnologyCodexis, Inc.
Oct 2, 20252025/0304924ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDSBiotechnologyCodexis, Inc.
Sep 18, 20252025/0290049BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDSBiotechnologyCodexis, Inc.
What it applied for, 2024 to 2025: Biotechnology 70 · Pharmaceuticals 3.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton CDXS · research, not advice